Share Buyback

As Bell Let's Talk Day returns, a look at its 16-year, $194M journey reveals a complex legacy of groundbreaking awareness, crucial funding, and intense controversy.

As gold nears $4,700/oz, Cerrado Gold ends its price cap program and launches a share buyback, a dual move to maximize profits and shareholder value.

The Chinese digital freight giant commits to returning over 50% of annual profit to investors, signaling a new era of maturity for the tech sector.

Toro Corp. paid a massive special dividend, exciting investors. We dig into the cash-vs-stock option, market reaction, and what it means for the firm's future.

For the third straight year, Carlisle Companies has been crowned a top firm by investors. We explore the strategy, transparency, and ESG focus behind the win.

A new report reveals investors are hungry for growth, pushing firms to reinvest, but high valuations and global uncertainty temper their bullish outlook.

The successful offering highlights investor appetite for structured income products tied to Canada's resilient banking sector amid economic uncertainty.

Amid a bold pivot to blockchain, Sharps Technology doubles down with an advisor lock-up and a $100M buyback, signaling conviction in its hybrid future.

A new Egan-Jones report argues that while founders get the fame, it's the successor CEOs at Apple, Microsoft, and Alphabet who build enduring value.

With global milk oversupply and shifting consumer tastes, all eyes are on Saputo's Feb. 5 earnings for signs of strategic success and market health.

As foreign investors accumulate shares at valuation lows, Shoucheng Holdings leverages its financial might and strategic robotics portfolio to redefine its future.

As MarketAxess preps its Q4 results, investors weigh a mixed 2025. Will its strategic shifts in a volatile fixed-income market deliver on growth promises?

Antero Midstream announces its 45th straight dividend and a $48M share buyback, signaling financial strength as investors await Q4 2025 earnings.

With a promising brain injury drug and no approved rivals, Oragenics heads to a tax-haven investor summit to secure funding for its next critical phase.

Propanc Biopharma is taking a 100-year-old cancer treatment concept into modern human trials, targeting advanced tumors and expanding into fibrosis.

Investors and HR leaders watch as Unum prepares to release its Q4 results and 2026 strategy in a rapidly evolving workplace benefits landscape.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

EfTEN Real Estate Fund reports its best-ever operating results, proposing an 8% dividend hike, while a minor portfolio revaluation hints at market shifts.

Hong Kong's 3E Network completes a $2M financing round, fueling its strategic shift into the competitive global AI infrastructure market.

EpicQuest Education's CES award highlights its AI university plans, but a closer look reveals a complex picture of innovation, market hype, and financial risk.